Eli Lilly And Co (NYSE:LLY) Downgraded to Sell at ValuEngine

ValuEngine downgraded shares of Eli Lilly And Co (NYSE:LLY) from a hold rating to a sell rating in a research note released on Saturday, ValuEngine reports.

A number of other research analysts also recently issued reports on LLY. JPMorgan Chase & Co. increased their price objective on Eli Lilly And Co from $175.00 to $190.00 and gave the stock an overweight rating in a report on Wednesday, June 17th. Bank of America reiterated a buy rating and set a $180.00 price objective on shares of Eli Lilly And Co in a report on Friday, June 19th. Cfra increased their price objective on Eli Lilly And Co from $146.00 to $167.00 and gave the stock a hold rating in a report on Friday, April 24th. Cantor Fitzgerald increased their price objective on Eli Lilly And Co from $156.00 to $185.00 and gave the stock an overweight rating in a report on Friday, April 24th. Finally, UBS Group downgraded Eli Lilly And Co from a buy rating to a neutral rating and increased their price objective for the stock from $157.00 to $158.00 in a report on Monday, April 20th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $168.58.

Shares of NYSE LLY traded down $2.71 during mid-day trading on Friday, reaching $150.29. 5,342,109 shares of the company’s stock were exchanged, compared to its average volume of 2,630,266. The firm has a market capitalization of $143.74 billion, a price-to-earnings ratio of 24.40, a PEG ratio of 1.32 and a beta of 0.26. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 4.37. The business has a fifty day simple moving average of $160.88 and a 200 day simple moving average of $148.62. Eli Lilly And Co has a twelve month low of $101.36 and a twelve month high of $170.75.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Thursday, July 30th. The company reported $1.89 EPS for the quarter, topping the Zacks’ consensus estimate of $1.58 by $0.31. The company had revenue of $5.50 billion for the quarter, compared to analyst estimates of $5.77 billion. Eli Lilly And Co had a return on equity of 200.78% and a net margin of 24.48%. Eli Lilly And Co’s revenue was down 2.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.50 earnings per share. Equities research analysts predict that Eli Lilly And Co will post 7.3 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a dividend of $0.74 per share. The ex-dividend date is Thursday, August 13th. This represents a $2.96 annualized dividend and a dividend yield of 1.97%. Eli Lilly And Co’s dividend payout ratio is currently 49.01%.

In related news, major shareholder Lilly Endowment Inc sold 53,770 shares of Eli Lilly And Co stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $161.54, for a total transaction of $8,686,005.80. Following the completion of the sale, the insider now directly owns 111,798,270 shares of the company’s stock, valued at approximately $18,059,892,535.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Alfonso G. Zulueta sold 17,000 shares of Eli Lilly And Co stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $162.94, for a total value of $2,769,980.00. Following the sale, the senior vice president now directly owns 39,646 shares of the company’s stock, valued at $6,459,919.24. The disclosure for this sale can be found here. Insiders have sold a total of 555,236 shares of company stock valued at $91,393,391 over the last quarter. 0.09% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the stock. Cpwm LLC lifted its holdings in Eli Lilly And Co by 0.7% during the 1st quarter. Cpwm LLC now owns 9,349 shares of the company’s stock worth $1,297,000 after purchasing an additional 65 shares during the last quarter. Old North State Trust LLC lifted its holdings in Eli Lilly And Co by 1.2% during the 2nd quarter. Old North State Trust LLC now owns 5,660 shares of the company’s stock worth $929,000 after purchasing an additional 66 shares during the last quarter. Endurance Wealth Management Inc. raised its holdings in Eli Lilly And Co by 1.6% in the 2nd quarter. Endurance Wealth Management Inc. now owns 4,141 shares of the company’s stock valued at $680,000 after acquiring an additional 66 shares in the last quarter. Parcion Private Wealth LLC raised its holdings in Eli Lilly And Co by 3.5% in the 2nd quarter. Parcion Private Wealth LLC now owns 1,929 shares of the company’s stock valued at $322,000 after acquiring an additional 66 shares in the last quarter. Finally, Hotaling Investment Management LLC raised its holdings in Eli Lilly And Co by 2.7% in the 2nd quarter. Hotaling Investment Management LLC now owns 2,534 shares of the company’s stock valued at $416,000 after acquiring an additional 67 shares in the last quarter. 77.32% of the stock is owned by institutional investors and hedge funds.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: How to calculate the annual rate of depreciation

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.